Where can I find the detailed financial results for Pfizer's first quarter of 2026?

The detailed financial results for Pfizer's first quarter of 2026 are provided in the press release dated May 5, 2026, which is furnished as Exhibit 99 in this 8-K filing. You should refer to that document for specific figures and analysis.

What key financial metrics should I look for in the press release?

Investors should look for key metrics such as revenue, net income, earnings per share (EPS), profit margins, and segment-specific performance. Additionally, any forward-looking guidance or updates on drug pipelines and commercial performance would be critical.

Does this 8-K filing contain the full financial statements?

No, this Form 8-K filing primarily serves to announce the release of financial results and incorporates the press release by reference. The full, detailed financial statements for Q1 2026 are not included directly within the 8-K document itself but are found in the accompanying press release.

What is the significance of the information not being 'filed' under Section 18?

The statement that the information furnished under Item 2.02 (and Exhibit 99) is not deemed 'filed' for the purposes of Section 18 of the Exchange Act means that Pfizer is not subject to the same level of liability under that specific section for the content of the press release as they would be for information formally filed with the SEC. This is a standard disclosure for earnings releases furnished under Item 2.02.

PFE 8-K: Earnings & Results

Summary

Pfizer Inc. (PFE) has filed a Form 8-K on May 5, 2026, to report its financial results for the first quarter of 2026. The filing primarily incorporates by reference a press release, dated the same day, which details the company's performance and financial condition for the period. Investors should refer to the furnished press release (Exhibit 99) for specific financial data, operational highlights, and management commentary regarding Q1 2026. The 8-K itself serves as notification of the release of this information and does not contain detailed financial statements or disclosures beyond referencing the press release. While this 8-K filing doesn't provide the detailed figures directly within its text, it signals that Pfizer has communicated its Q1 2026 earnings. The furnished press release is the critical document for investors seeking to understand revenue, profitability, segment performance, and any forward-looking guidance or significant business developments announced by Pfizer during the reporting period. The filing also notes the inclusion of an interactive data file for enhanced data accessibility.

Key Highlights

1Pfizer Inc. (PFE) announced Q1 2026 financial results via an 8-K filing on May 5, 2026.
2The primary disclosure of financial information is contained within an attached press release (Exhibit 99).
3Investors are directed to the press release for detailed Q1 2026 financial performance and operational updates.
4The filing serves as formal notification of the earnings release and provides the press release as the source of detailed data.
5Information furnished under Item 2.02 is not deemed 'filed' for certain legal purposes, emphasizing the press release as the standalone disclosure vehicle for this event.
6The filing includes the Cover Page Interactive Data File for XBRL data accessibility.

PFIZER INC 8-K Report, Financial Results (May 5, 2026)

Summary

Key Highlights

Frequently Asked Questions